Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Telemedicine Strategy After MI Scores a Win in TELE-ACS

News Conference News ACC 2024

Telemedicine Strategy After MI Scores a Win in TELE-ACS

April 12, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

News Conference News ACC 2024

Long-Awaited RCT Data Show Survival Benefit With Impella CP: DanGer Shock

April 07, 2024

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

News Conference News ACC 2023

Wrist-Worn Sensor May Help Detect Elevated Troponin in ACS

March 06, 2023

Global STEMI Initiative Helps Low- and Middle-Income Countries Achieve Better Metrics

News Conference News ACC 2021

Global STEMI Initiative Helps Low- and Middle-Income Countries Achieve Better Metrics

May 24, 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

News Conference News ACC 2021

Even With Stent Cards, Patients Often Hazy on PCI Details Years Later

Michael O'Riordan

May 11, 2021

STEMI App Lowers Time to Treatment Across Regional Health System

News Conference News ACC 2021

STEMI App Lowers Time to Treatment Across Regional Health System

Yael L. Maxwell

May 07, 2021

Sonothrombolysis for Acute STEMI? High-Frequency Microbubbles Show Promise in MRUSMI

News Conference News ACC 2019

Sonothrombolysis for Acute STEMI? High-Frequency Microbubbles Show Promise in MRUSMI

March 27, 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

News Conference News ACC 2018

Reducing Co-payments for P2Y12 Inhibitors Upped Ticagrelor Use but Didn’t Budge MACE: ARTEMIS

March 11, 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

News Conference News ACC 2018

Bad BVS News: Analysis Points to Fast Reaction by Interventionalists to Absorb Safety Issues

Michael O'Riordan

March 11, 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

News Conference News ACC 2018

ACC 2018: More PCSK9 Outcomes, Antiplatelet Insights, and LifeVest Data at Last

March 05, 2018

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

April 13, 2016

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

March 14, 2015

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Conference News ACC 2012

INFUSE-AMI: Bolus Abciximab Works, Thrombus Aspiration Doesn’t for Large STEMI

March 25, 2012

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.